Oculis Management to Attend September Investor Conferences
Oculis Holding AG (NASDAQ: OCS), a biopharmaceutical company based in Switzerland, is set to take part in a series of investor conferences this upcoming September. The company specializes in developing pioneering treatments for ophthalmic and neuro-ophthalmic conditions, addressing significant medical needs.
Upcoming Conference Schedule
Wells Fargo Healthcare Conference
This conference will take place from September 3 to 5. Oculis' Chief Executive Officer, Riad Sherif, M.D., and Chief Financial Officer, Sylvia Cheung, are scheduled to attend this important healthcare event in Boston.
H.C. Wainwright 27th Annual Global Investment Conference
On September 8–10, Oculis will have a presence at this notable conference in New York. Dr. Riad Sherif is set to participate in a fireside chat on September 8, highlighting the company's ongoing developments.
Baird Global Healthcare Conference
Following the Wainwright conference, Oculis will present updates at the Baird Global Healthcare Conference on September 9–10. Dr. Sherif is expected to provide insights about the company during a scheduled update on September 9.
Pareto Securities 16th Annual Healthcare Conference
On September 16, Oculis will be featured in Stockholm, where Páll Ragnar Jóhannesson, Chief Business Officer, will deliver a company update.
Leerink Partners Biopharma Summit
The final event of the month for Oculis is the Leerink Partners Biopharma Summit, held from September 17–19 in Healdsburg. Dr. Sherif will represent the company during this gathering.
One-on-One Meetings
During the conferences, Oculis will be available for one-on-one meetings with potential investors. Interested parties are encouraged to reach out to their respective representatives at the sponsoring institutions to arrange these critical discussions.
Webcasts and Event Updates
Oculis will share webcast links and additional information on their official website under the investors section, making it easy for stakeholders to stay informed about the company’s progress and insights from the conferences.
About Oculis
Oculis is on the frontlines of biopharmaceutical innovation, particularly in ophthalmology and neuro-ophthalmology. The company is advancing its late-stage pipeline, which includes a range of promising candidates aimed at treating various conditions. Their lead product, OCS-01, is an eye drop currently undergoing pivotal registration studies, targeting diabetic macular edema. Additionally, Privosegtor (OCS-05) is in Phase 2 trials and focuses on acute optic neuritis, while Licaminlimab (OCS-02), also in Phase 2, aims to offer personalized treatment for dry eye disease.
The Oculis team, with their rich blend of experience and expertise, is dedicated to turning innovative ideas into therapeutic realities. Their headquarters in Switzerland is complemented by a strong presence in the U.S. and Iceland, ensuring a global approach to healthcare advancements.
Contact Information
For further inquiries or information, Ms. Sylvia Cheung, CFO, can be reached at sylvia.cheung@oculis.com. For investor relations, Corey Davis, Ph.D., from LifeSci Advisors is available at cdavis@lifesciadvisors.com. Media-related questions can be directed to ICR Healthcare at oculis@icrhealthcare.com.
Frequently Asked Questions
What is Oculis Holding AG's primary focus?
Oculis is focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs.
When is Oculis participating in the Wells Fargo Conference?
The Wells Fargo Healthcare Conference is scheduled for September 3-5, where Oculis management will be present.
Who will represent Oculis at the H.C. Wainwright conference?
Riad Sherif, M.D., the Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Conference on September 8.
What therapeutic areas does Oculis address?
Oculis targets various ophthalmic and neuro-ophthalmic conditions, including diabetic macular edema and acute optic neuritis.
How can investors schedule meetings with Oculis during the conferences?
Interested investors are encouraged to contact their representatives at the sponsoring institutions to schedule one-on-one meetings during the conferences.
